Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GALNT8 Antisense Upstream 1 (GAU1)
- Target
- GAU1
- Molecular classification
- Other (long non-coding RNA)
01
Overview
GAU1 is a long non-coding RNA that plays a significant role in regulating the expression of nearby genes, notably GALNT8. It is involved in promoting cell cycle and proliferation in cancer cells, particularly in colorectal cancer. GAU1's overexpression is associated with poor prognosis in CRC patients. It acts as an oncogenic factor by enhancing tumor growth and rendering cancer cells more sensitive to certain chemotherapy agents. GAU1 is also implicated in other cancers such as neuroblastoma, where it similarly promotes tumorigenesis.
- Other names
- GALNT8-DTGALNT8 divergent transcript
02
Mechanism of action
GAU1 regulates GALNT8 expression, which in turn influences cell proliferation and response to chemotherapy.
03
Biological functions
Cell cycleCell proliferationGene regulation
04
Disease associations
Cancer (specifically colorectal and neuroblastoma)
05
Safety considerations
None directly related to GAU1 as a therapeutic target, but it is involved in cancer progression.
06
Interacting drugs
oxaliplatin
07
Biomarkers
Potential biomarker for CRC prognosis due to its overexpression in CRC and correlation with poor prognosis.
Beyond the preview
Go deeper on GALNT8 Antisense Upstream 1 (GAU1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GALNT8 Antisense Upstream 1 (GAU1).